Current investments

We have one or more companies open for investments. Please login or create an account to learn more and invest.

Completed investments

SAGA Diagnostics

SAGA Diagnostics develops ultrasensitive liquid biopsy tests for early detection of cancer relapse and personalized cancer treatment. The tests are based on the company’s proprietary technologies for analyzing circulating tumor DNA (ctDNA).

Read more

Capitainer

Capitainer supplies intelligent solutions for self-sampling of blood and plasma. The product qDBS is based on DBS (Dried Blood Spot) technology and is designed for easy home sampling of blood with high precision.

Read more

Synartro – 2

Synartro is developing a unique treatment for knee osteoarthritis by combining two proven drugs, which will offer an effective and safe alternative to today’s treatments.

Read more

PharmNovo

PharmNovo develops drugs for chronic pain based on a new type of selective delta opioids. The main candidate PN6047 shows promising results on effective pain relief without negative side effects.

Read more
Show more

Exits

Cartana

Cartana’s patent-applied research tool revolutionizes the possibility of analyzing tissue samples, providing pharmaceutical companies with important information in their quest for new treatments.

Read more

Inhalation Sciences

Inhalation Science’s technology is used by leading players in the chemical and pharmaceutical sectors to study how airborne particles affect the human body.

Read more

Attana

With Attana’s patented technology, pharmaceutical companies can evaluate, in an early development stage, how drug candidates impact the body and can identify the risk of side effects.

Read more

Lipigon Pharmaceuticals

Lipigon develops orphan drugs for illnesses due to disorders in how the body handles fat. The company’s major program, Lipsense, focuses on the illness, HoFH, where there is, today, no sufficient treatment.

Read more
Show more